Related items
Showing items related by title, author, creator and subject.
-
Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events A Meta-Analysis of Statin Trials
Boekholdt, SM; Hovingh, GK; Mora, S; Arsenault, BJ; Amarenco, P; Pedersen, TR; LaRosa, JC; Waters, DD; DeMicco, DA; Simes, RJ (2014-08-05) -
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz, GG; Szarek, M; Bittner, VA; Diaz, R; Goodman, SG; Jukema, JW; Landmesser, U; López-Jaramillo, P; Manvelian, G; Pordy, R (2021-08-03)BACKGROUND: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum ... -
NNT is a key regulator of adrenal redox homeostasis and steroidogenesis in male mice.
Meimaridou, E; Goldsworthy, M; Chortis, V; Fragouli, E; Foster, PA; Arlt, W; Cox, R; Metherell, LA (2018-01)Nicotinamide nucleotide transhydrogenase, NNT, is a ubiquitous protein of the inner mitochondrial membrane with a key role in mitochondrial redox balance. NNT produces high concentrations of NADPH for detoxification of ...